The Pure-Play Psychedelic Stocks Index Declined 18.7% On Tuesday

This article tracks the performance of the 31 biopharmaceutical companies involved in the research and development of psychedelic compounds to treat mental health issues. 12 of the 15 constituents in the Pure-Play Psychedelic Stocks Index declined.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.